<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12266">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00502216</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAA_TOL-AA15632</org_study_id>
    <secondary_id>P50AA015632</secondary_id>
    <secondary_id>NIH Grant P50-AA15632</secondary_id>
    <secondary_id>NIH Grant K12-DA00167</secondary_id>
    <nct_id>NCT00502216</nct_id>
  </id_info>
  <brief_title>Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers</brief_title>
  <official_title>Naltrexone and Varenicline: Weight Gain and Tolerability in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of naltrexone (Depade) and
      varenicline (Chantix) minimizes post-smoking cessation weight gain and how well the
      combination is tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Varenicline, a medication recently approved by the FDA, results in smoking cessation rates
      as high as 50%, significantly better than bupropion or placebo. However, varenicline does
      not reduce post-cessation weight gain, so weight concerns may keep some smokers from taking
      advantage of this effective therapy.

      A potential solution would be to combine varenicline with an agent that reduces weight gain.
      In this regard, several studies have shown that naltrexone reduces weight gain (O'Malley et
      al., 2006; Toll et al., 2007).

      This effect appears to be dose dependent, favoring lower doses (i.e., 25 mg daily). Thus,
      the proposed study seeks to conduct a pilot clinical trial of low dose naltrexone (25 mg
      daily) compared to placebo for minimizing weight gain in combination with varenicline for
      smoking cessation. Forty individuals who smoke at least 10 cigarettes per day will receive
      open-label varenicline for 12 weeks according to the recommended titration schedule up to 1
      mg varenicline twice daily. Subjects will be randomized to receive either placebo or 25 mg
      naltrexone daily, with treatment starting at the quit date (after 1 week on varenicline to
      minimize nausea, a side effect of both varenicline and naltrexone) and continuing for 11
      weeks. Subjects will take 12.5 mg naltrexone daily for the first week and 25 mg naltrexone
      daily for the next 10 weeks of treatment. In an effort to uncover mechanisms for
      naltrexone's weight suppressant effects, an experiment will be conducted using food odors
      and food consumption to examine naltrexone's effects on palatability, incentive value, and
      alliesthesia.

      This experiment will be conducted pretreatment and after 2 weeks on naltrexone. The primary
      aim of this pilot study is to examine weight gain in participants who complete the clinical
      trial treatment. Weight gain for those who are continuously abstinent for the last 4 weeks
      of treatment and rates of adverse events will be secondary outcomes. The effects of
      naltrexone on odor/food palatability, incentive value, and alliesthesia will be exploratory
      outcomes. Effect size estimates for weight gain will be generated for a NIH grant
      application.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Weight Gain in Treatment Completers</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Gain in Participants Who Are Continuously Abstinent for the Last 4 Weeks of Treatment</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of the Combination of 25 mg Naltrexone and 2 mg Varenicline</measure>
    <time_frame>11 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Smoking</condition>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between the ages of 18 and 75

          2. Smoking 10 or more cigarettes per day

          3. Fewer than 3 months of smoking abstinence in the past year

          4. Motivated to stop smoking

        Exclusion Criteria:

          1. Current use of opiates, and/or a urine toxicology screen positive for opiates

          2. Chronic pain conditions necessitating opioid treatment (naltrexone, an opioid
             antagonist will make these medications ineffective)

          3. Evidence of significant hepatocellular injury as evidence by AST or ALT &gt;3 x normal
             or elevated bilirubin

          4. History of cirrhosis

          5. Any serious or unstable disease within 6 months

          6. Seizure risk

          7. Diabetes mellitus requiring insulin or oral hypoglycemic medications

          8. Hepatic or renal impairment

          9. Use of a monoamine oxidase inhibitor in the prior 14 days

         10. Clinically significant cardiovascular disease within 6 months

         11. Uncontrolled hypertension

         12. Baseline systolic blood pressure higher than 150 mm Hg or diastolic blood pressure
             higher than 95 mm Hg

         13. Severe chronic obstructive pulmonary disease

         14. History of cancer (except treated basal cell or squamous cell carcinoma of the skin)

         15. History of clinically significant allergic reactions

         16. Major depressive disorder within the past year requiring treatment

         17. History of or current panic disorder, psychosis, bipolar disorder, or eating
             disorders

         18. Alcohol or drug abuse/dependency within the past year

         19. Use of another investigational drug within 30 days

         20. Intention to donate blood or blood products during the treatment phase of the study

         21. Use of tobacco products other than cigarettes or use of marijuana

         22. Use of nicotine replacement therapy, clonidine, varenicline, bupropion, or
             nortriptyline within the month prior to enrollment or intention to use medication
             that might interfere with study medication

         23. Body Mass Index (calculated as weight in kilograms divided by the square of height in
             meters) less than 15 or greater than 38 or weight less than 45 kg.

         24. Females of childbearing potential who are pregnant, nursing, or not practicing
             effective contraception (oral injectable, or implantable contraceptives, intrauterine
             device, or barrier method with spermacide)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin A. Toll, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine Substance Abuse Treatment Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <lastchanged_date>August 30, 2010</lastchanged_date>
  <firstreceived_date>July 13, 2007</firstreceived_date>
  <firstreceived_results_date>June 3, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Benjamin Toll, Ph.D., Assistant Professor</name_title>
    <organization>Yale University</organization>
  </responsible_party>
  <keyword>Tobacco</keyword>
  <keyword>Smoking</keyword>
  <keyword>Weight</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>Varenicline</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Varenicline + Naltrexone</title>
          <description>Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day</description>
        </group>
        <group group_id="P2">
          <title>Varenicline + Placebo</title>
          <description>Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline + Naltrexone</title>
          <description>Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day</description>
        </group>
        <group group_id="B2">
          <title>Varenicline + Placebo</title>
          <description>Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50.29" spread="11.08"/>
                <measurement group_id="B2" value="42.42" spread="9.57"/>
                <measurement group_id="B3" value="46.55" spread="11.00"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="27"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weight Gain in Treatment Completers</title>
        <time_frame>baseline and 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subpopulation of participants who reported quitting smoking</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline + Naltrexone</title>
            <description>Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day</description>
          </group>
          <group group_id="O2">
            <title>Varenicline + Placebo</title>
            <description>Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Weight Gain in Treatment Completers</title>
            <units>Pounds</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.35" spread="6.61"/>
                  <measurement group_id="O2" value="4.14" spread="5.15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Gain in Participants Who Are Continuously Abstinent for the Last 4 Weeks of Treatment</title>
        <time_frame>4 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of the Combination of 25 mg Naltrexone and 2 mg Varenicline</title>
        <time_frame>11 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Varenicline + Naltrexone</title>
          <description>Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day</description>
        </group>
        <group group_id="E2">
          <title>Varenicline + Placebo</title>
          <description>Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Acid reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin Toll, Ph.D.</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>203-974-5767</phone>
      <email>benjamin.toll@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
